Aktienanalyse zu Corcept Therapeutics Inc (CORT)CORTCorcept Therapeutics Inc

Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Corcept Therapeutics Inc is currently not a strong buy due to its low RSI of 23.981, indicating oversold conditions, and a recent insider selling increase of 271.06%. However, the company has a promising forward P/E of 19.305 and a significant YTD change of +188.38%, suggesting potential for recovery. The main risk is the recent negative sentiment from insiders and the market, which could impact future performance.

5 analysts cover CORT: 3 rate it Buy, 0 Hold and 2 Sell. The average price target is 91.00.